Literature DB >> 15863171

Futility: clinical decisions at the end-of-life in women with ovarian cancer.

Vivian E von Gruenigen1, Barbara J Daly.   

Abstract

OBJECTIVE: The purpose of this article is to provide a review of the clinical meaning of futility, discuss current normative uses of futility assessments and propose guidelines for clinicians to use in dialogue regarding treatment decisions for patients with advanced ovarian cancers.
METHODS: We performed a MEDLINE literature search of relevant clinical articles for this review that discussed futility and the application to women with ovarian cancer.
RESULTS: Medical futility refers to treatments that serve no physiologic, quantitative or qualitative meaningful purpose. Despite the growth in options focused on symptom management rather than disease eradication, including hospice programs and the more recent development of palliative care programs, there is evidence that many patients continue to receive aggressive interventions, including chemotherapy, until days before their death. While the legal and moral acceptability of treatment limitation is well established, clarity in establishing goals of care, timing of the transition from cure to palliation and communication of specific decisions to withhold further aggressive interventions remain problematic for both patients and clinicians.
CONCLUSIONS: There continues to be a distinct need for both better understanding of the dynamics of patient choice and increased education of physicians in addressing end-of-life care planning. It is essential that we continue to test specific communication and supportive interventions that will improve our ability to help patients avoid the burden of futile therapy while maintaining hope.

Entities:  

Keywords:  Death and Euthanasia; Professional Patient Relationship

Mesh:

Year:  2005        PMID: 15863171     DOI: 10.1016/j.ygyno.2005.01.031

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  Hope against hope in cancer at the end of life.

Authors:  Natalie A Pattison; Christopher Lee
Journal:  J Relig Health       Date:  2009-06-16

2.  Use of unnecessary medications by patients with advanced cancer: cross-sectional survey.

Authors:  Angelo Fede; Michele Miranda; Daniella Antonangelo; Ligia Trevizan; Henrique Schaffhausser; Bruno Hamermesz; Camile Zimmermann; Auro Del Giglio; Rachel P Riechelmann
Journal:  Support Care Cancer       Date:  2010-07-21       Impact factor: 3.603

3.  Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study.

Authors:  Katrin M Sjoquist; Michael L Friedlander; Rachel L O'Connell; Merryn Voysey; Madeleine T King; Martin R Stockler; Amit M Oza; Kim Gillies; Julie K Martyn; Phyllis N Butow
Journal:  Oncologist       Date:  2013-10-09

4.  Futile medication use in terminally ill cancer patients.

Authors:  Rachel P Riechelmann; Monika K Krzyzanowska; Camilla Zimmermann
Journal:  Support Care Cancer       Date:  2008-11-22       Impact factor: 3.603

5.  Assessment of implementation of an order protocol for end-of-life symptom management.

Authors:  Anne M Walling; Katherine Brown-Saltzman; Tod Barry; Rita Jue Quan; Neil S Wenger
Journal:  J Palliat Med       Date:  2008-07       Impact factor: 2.947

Review 6.  Drugs, cancer and end-of-life care: a case study of pharmaceuticalization?

Authors:  Courtney Davis
Journal:  Soc Sci Med       Date:  2014-12-02       Impact factor: 4.634

7.  Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future.

Authors:  Nicoletta Colombo; Domenica Lorusso; Paolo Scollo
Journal:  Int J Gynecol Cancer       Date:  2017-07       Impact factor: 3.437

8.  Palliative Care for Patients with Gynecologic Cancer in Japan:zzm321990A Japan Society of Gynecologic Palliative Medicine (JSGPM)zzm321990Survey

Authors:  Masayuki Futagami; Yoshihito Yokoyama; Tetsumi Sato; Kazuyoshi Hirota; Muneaki Shimada; Etsuko Miyagi; Nao Suzuki; Masaki Fujimura
Journal:  Asian Pac J Cancer Prev       Date:  2016-10-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.